Comparing a new DLL3 PET/CT scan to standard scans for neuroendocrine cancer
Part of Cancer clinical trials.
This study tests a new type of PET/CT scan that looks for a marker called DLL3 on neuroendocrine cancer cells. It aims to see if this scan finds tumors better than standard scans, which could help guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a confirmed neuroendocrine tumor (like small cell lung cancer, neuroendocrine prostate cancer, or a gastroenteropancreatic neuroendocrine tumor).
- Your cancer has spread to at least two spots in your body (seen on CT, MRI, or PET scan).
- You are able to be up and about (able to care for yourself, but may not be able to work).
- You haven't had chemotherapy, targeted therapy, or other cancer treatments in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This trial uses a special PET/CT scan that targets a substance called DLL3, found on some cancer cells, to see if doctors can better detect or monitor neuroendocrine carcinoma. It may help you and your doctor get clearer information about your cancer.
This trial tests a special PET/CT imaging scan that may help doctors find where small cell lung cancer (and some related tumors) are in the body using a DLL3 target. It’s a Phase 1/2 study, mainly to see how well the scan detects tumors and guides care.
This trial tests a new drug called 177Lu-DTPA-SC16.56, which delivers radiation directly to cancer cells that have a specific marker called DLL3. It is for people with high-grade neuroendocrine lung or prostate cancer that has spread and gotten worse after at least one round of chemotherapy.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.